A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

Biomarkers have become an essential component of Alzheimer disease (AD) research and because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used in cognitive aging research. A number of current issues suggest that an unbiased descriptive classification scheme for these biomarkers would be useful. We propose the “A/T/N” system in which 7 major AD biomarkers are divided into 3 binary categories based on the nature of the pathophysiology that each measures. “A” refers to the value of a β-amyloid biomarker (amyloid PET or CSF Aβ42); “T,” the value of a tau biomarker (CSF phospho tau, or tau PET); and “N,” biomarkers of neurodegeneration or neuronal injury ([18F]-fluorodeoxyglucose–PET, structural MRI, or CSF total tau). Each biomarker category is rated as positive or negative. An individual score might appear as A+/T+/N−, or A+/T−/N−, etc. The A/T/N system includes the new modality tau PET. It is agnostic to the temporal ordering of mechanisms underlying AD pathogenesis. It includes all individuals in any population regardless of the mix of biomarker findings and therefore is suited to population studies of cognitive aging. It does not specify disease labels and thus is not a diagnostic classification system. It is a descriptive system for categorizing multidomain biomarker findings at the individual person level in a format that is easy to understand and use. Given the present lack of consensus among AD specialists on terminology across the clinically normal to dementia spectrum, a biomarker classification scheme will have broadest acceptance if it is independent from any one clinically defined diagnostic scheme.

[1]  D. Perani.  Faculty Opinions recommendation of PET imaging of tau deposition in the aging human brain. , 2017 .

[2]  L. Wilkins.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2017, Neurology.

[3]  C. Jack,et al.  Effect of intellectual enrichment on AD biomarker trajectories , 2016, Neurology.

[4]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[5]  A. Fagan,et al.  Suspected non-Alzheimer disease pathophysiology — concept and controversy , 2016, Nature Reviews Neurology.

[6]  C. Jack,et al.  Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study , 2016, The Lancet Neurology.

[7]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[8]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[9]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[10]  M. Weiner,et al.  Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[11]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[12]  Kerstin Heurling,et al.  [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology , 2015, Alzheimer's & Dementia.

[13]  G. Chételat,et al.  Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease , 2015, The Journal of Neuroscience.

[14]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[15]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[16]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[17]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[18]  H. Braak,et al.  PART is part of Alzheimer disease , 2015, Acta Neuropathologica.

[19]  Simone Lista,et al.  Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future , 2015, Expert review of neurotherapeutics.

[20]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[21]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[22]  Miranka Wirth,et al.  Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions , 2014, Neurology.

[23]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[24]  N. Laskaris,et al.  Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[25]  K. Blennow,et al.  Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. , 2014, JAMA neurology.

[26]  Young T. Hong,et al.  Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. , 2014, JAMA neurology.

[27]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[28]  Cindee M. Madison,et al.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.

[29]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[30]  Gaël Chételat,et al.  Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.

[31]  K. Blennow,et al.  Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections , 2013, Journal of Neurology.

[32]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[33]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[34]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[35]  L. Whalley,et al.  Childhood socioeconomic status and adult brain size: Childhood socioeconomic status influences adult hippocampal size , 2012, Annals of neurology.

[36]  C. Jack,et al.  Modifiable factors that alter the size of the hippocampus with ageing , 2012, Nature Reviews Neurology.

[37]  Nazahah Mustafa,et al.  The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. , 2011, Brain : a journal of neurology.

[38]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[39]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[40]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[41]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[42]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[43]  Nick C. Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .

[44]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[45]  C. Duyckaerts.  Tau pathology in children and young adults: can you still be unconditionally baptist? , 2011, Acta Neuropathologica.

[46]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[47]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[48]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[49]  J. Duffy,et al.  Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. , 2010, Archives of neurology.

[50]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[51]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[52]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[53]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[54]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[55]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[56]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[57]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[58]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[59]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[60]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[61]  K. Blennow,et al.  Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury , 2006, Neurology.

[62]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[63]  K. Blennow,et al.  Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease , 2006, Neurobiology of Aging.

[64]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[65]  R. Gräsbeck.  The evolution of the reference value concept , 2004, Clinical chemistry and laboratory medicine.

[66]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[67]  J. Whitworth,et al.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension , 2003, Journal of hypertension.

[68]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[69]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[70]  K. Blennow,et al.  Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy , 2003 .

[71]  K. Blennow,et al.  Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. , 2003, Movement disorders : official journal of the Movement Disorder Society.

[72]  K. Blennow,et al.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.

[73]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.